Subsequently, Kamphorst et al. observed that the proliferation of peripheral PD-1+ CD8+ T cells within 4 weeks of anti-PD-(L)1 therapy in patients with NSCLC was associated with good clinical response (37). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.